CTTI ushered in 2021 with a new vision for Transforming Trials 2030 – one that requires cross-system collaboration from the entire research and healthcare community to create true and lasting change for better clinical trials by 2030.

On behalf of everyone at CTTI, thank you for joining us on this ambitious journey this year. Your contributions to pushing the boundaries for what can be done in clinical research and your dedication to creating improvements across the clinical trials community are truly making an impact. We are grateful for the opportunity to work with you and are proud to have your support.

Some of the accomplishments you have made possible in 2021 include:

• Making significant headway in creating solutions to support the first of the five pillars of Transforming Trials 2030 – “Patient-Centered & Easily Accessible” – through three key projects:
  • Decentralized Clinical Trials Update in Response to COVID-19
  • Obtaining Reliability and Acceptance of Meaningful, Digitally-Derived Novel Endpoints
  • Increasing Diversity in Clinical Trials

• Laying the foundations for the other vision pillars including:
  • The second pillar – “Fully Integrated into Health Processes” – which is supported by our Trials in Health Care Settings
  • The third pillar – “Designed with a Quality Approach” – which is furthered by our convening of global web conferences and developing new case studies.
  • The fourth pillar – “Maximally Leveraging All Available Data” – which is being driven by our gov Reporting Challenges project.
  • And finally, our efforts to make the HABP/VABP study data publicly available are advancing the fifth pillar – “Improve Public Health.”

• Sharing best practices and learnings from across the clinical trials community by:
  • Launching our new Building Better Trials: Case Study Exchange, featuring more than 40 case studies on best practices and examples of CTTI’s work in action;
  • Collaborating with the Duke-Margolis Center for Health Policy and FasterCures on a public summit on using master protocols in COVID-19 trials, and with the Digital Medicine Society (DiMe) and TransCelerate on a three-part webinar series on novel digital endpoints and;
  • Hosting a public webinar on COVID-19 treatment trials with clinical research experts.

As we look to 2022 under the leadership of our passionate new leader, Executive Director Sally Okun, we are excited to celebrate 15 years of increasing the quality and efficiency of clinical trials through the future-facing lens of our 2030 vision. This ambitious pursuit is the ultimate challenge, but also presents the biggest opportunity and reward.

As Socrates said, “The secret of change is to focus all of your energy, not on fighting the old, but on building the new.”

We look forward to “building the new” with you in 2022 and to making great strides toward achieving the audacious goal of transforming trials by 2030.

Best wishes for health and happiness to you and your families over this festive season and in the new year!